Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 7 studies | 36% ± 19% | |
endothelial cell | 6 studies | 24% ± 6% | |
epithelial cell | 5 studies | 25% ± 9% | |
GABAergic neuron | 5 studies | 34% ± 14% | |
neuron | 4 studies | 24% ± 4% | |
goblet cell | 4 studies | 25% ± 10% | |
ciliated cell | 3 studies | 20% ± 2% | |
interneuron | 3 studies | 38% ± 18% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 7 studies | 27% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 3189.64 | 245 / 245 | 100% | 39.84 | 502 / 502 |
ovary | 100% | 1768.62 | 180 / 180 | 100% | 37.92 | 429 / 430 |
kidney | 100% | 5176.33 | 89 / 89 | 100% | 46.62 | 898 / 901 |
pancreas | 100% | 3467.48 | 328 / 328 | 99% | 40.89 | 177 / 178 |
esophagus | 100% | 2580.55 | 1444 / 1445 | 99% | 44.81 | 182 / 183 |
intestine | 100% | 2859.94 | 965 / 966 | 99% | 48.31 | 523 / 527 |
breast | 100% | 3044.58 | 459 / 459 | 99% | 40.97 | 1107 / 1118 |
lung | 100% | 3191.53 | 576 / 578 | 99% | 41.00 | 1147 / 1155 |
stomach | 100% | 2761.35 | 359 / 359 | 99% | 50.83 | 283 / 286 |
skin | 100% | 7210.73 | 1809 / 1809 | 99% | 20.85 | 465 / 472 |
brain | 99% | 2973.14 | 2607 / 2642 | 100% | 34.21 | 703 / 705 |
uterus | 100% | 2101.42 | 170 / 170 | 98% | 33.83 | 449 / 459 |
bladder | 100% | 2563.24 | 21 / 21 | 98% | 33.77 | 492 / 504 |
adrenal gland | 99% | 1688.86 | 255 / 258 | 99% | 46.93 | 227 / 230 |
thymus | 100% | 2563.51 | 652 / 653 | 97% | 22.80 | 587 / 605 |
liver | 100% | 3403.86 | 226 / 226 | 96% | 26.63 | 390 / 406 |
adipose | 100% | 3003.14 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 1953.08 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 38.30 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 11.44 | 1 / 1 |
blood vessel | 100% | 1986.19 | 1331 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 1642.01 | 793 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 18.12 | 79 / 80 |
heart | 92% | 1329.23 | 794 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 73% | 1552.00 | 679 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 62% | 8.24 | 18 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0097191 | Biological process | extrinsic apoptotic signaling pathway |
GO_0032924 | Biological process | activin receptor signaling pathway |
GO_0007178 | Biological process | cell surface receptor protein serine/threonine kinase signaling pathway |
GO_0001701 | Biological process | in utero embryonic development |
GO_0010629 | Biological process | negative regulation of gene expression |
GO_1901165 | Biological process | positive regulation of trophoblast cell migration |
GO_0007165 | Biological process | signal transduction |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0018107 | Biological process | peptidyl-threonine phosphorylation |
GO_0032927 | Biological process | positive regulation of activin receptor signaling pathway |
GO_0071363 | Biological process | cellular response to growth factor stimulus |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0001942 | Biological process | hair follicle development |
GO_0038092 | Biological process | nodal signaling pathway |
GO_0045648 | Biological process | positive regulation of erythrocyte differentiation |
GO_0006468 | Biological process | protein phosphorylation |
GO_0046777 | Biological process | protein autophosphorylation |
GO_0007399 | Biological process | nervous system development |
GO_0000082 | Biological process | G1/S transition of mitotic cell cycle |
GO_0030308 | Biological process | negative regulation of cell growth |
GO_0043235 | Cellular component | receptor complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0009986 | Cellular component | cell surface |
GO_0005829 | Cellular component | cytosol |
GO_0048179 | Cellular component | activin receptor complex |
GO_0046332 | Molecular function | SMAD binding |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0048185 | Molecular function | activin binding |
GO_0004675 | Molecular function | transmembrane receptor protein serine/threonine kinase activity |
GO_0017002 | Molecular function | activin receptor activity |
GO_0019838 | Molecular function | growth factor binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0034711 | Molecular function | inhibin binding |
GO_0070411 | Molecular function | I-SMAD binding |
GO_0005515 | Molecular function | protein binding |
GO_0016361 | Molecular function | activin receptor activity, type I |
Gene name | ACVR1B |
Protein name | Activin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (Activin receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2) Activin A receptor type 1B |
Synonyms | ALK4 ACVRLK4 |
Description | FUNCTION: Transmembrane serine/threonine kinase activin type-1 receptor forming an activin receptor complex with activin receptor type-2 (ACVR2A or ACVR2B). Transduces the activin signal from the cell surface to the cytoplasm and is thus regulating a many physiological and pathological processes including neuronal differentiation and neuronal survival, hair follicle development and cycling, FSH production by the pituitary gland, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activin is also thought to have a paracrine or autocrine role in follicular development in the ovary. Within the receptor complex, type-2 receptors (ACVR2A and/or ACVR2B) act as a primary activin receptors whereas the type-1 receptors like ACVR1B act as downstream transducers of activin signals. Activin binds to type-2 receptor at the plasma membrane and activates its serine-threonine kinase. The activated receptor type-2 then phosphorylates and activates the type-1 receptor such as ACVR1B. Once activated, the type-1 receptor binds and phosphorylates the SMAD proteins SMAD2 and SMAD3, on serine residues of the C-terminal tail. Soon after their association with the activin receptor and subsequent phosphorylation, SMAD2 and SMAD3 are released into the cytoplasm where they interact with the common partner SMAD4. This SMAD complex translocates into the nucleus where it mediates activin-induced transcription. Inhibitory SMAD7, which is recruited to ACVR1B through FKBP1A, can prevent the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. Activin signal transduction is also antagonized by the binding to the receptor of inhibin-B via the IGSF1 inhibin coreceptor. ACVR1B also phosphorylates TDP2. . |
Accessions | F5H5Q2 ENST00000257963.9 [P36896-1] ENST00000536420.5 ENST00000415850.6 [P36896-3] ENST00000426655.6 [P36896-2] ENST00000541224.5 [P36896-4] P36896 ENST00000542485.1 [P36896-5] |